Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Price Target at $17.85

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have received a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

Several research analysts have commented on TVTX shares. Piper Sandler boosted their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th. Wedbush reiterated an “outperform” rating and set a $13.00 price target on shares of Travere Therapeutics in a report on Wednesday, April 17th. HC Wainwright upped their price target on shares of Travere Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday. Guggenheim reiterated a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Finally, Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th.

Travere Therapeutics Trading Down 2.4 %

Shares of TVTX stock opened at $5.26 on Wednesday. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88. The stock has a market cap of $400.33 million, a P/E ratio of -3.27 and a beta of 0.58. The stock has a 50 day simple moving average of $7.28 and a 200 day simple moving average of $7.65. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $22.75.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The business had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. On average, research analysts predict that Travere Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 19,122 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the sale, the chief executive officer now owns 350,600 shares of the company’s stock, valued at $3,050,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.71, for a total transaction of $41,494.44. Following the sale, the senior vice president now owns 80,720 shares of the company’s stock, valued at $703,071.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric M. Dube sold 19,122 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the sale, the chief executive officer now directly owns 350,600 shares in the company, valued at approximately $3,050,220. The disclosure for this sale can be found here. Insiders sold 34,773 shares of company stock worth $300,625 over the last three months. Company insiders own 3.75% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas boosted its position in shares of Travere Therapeutics by 9.6% during the 3rd quarter. Teacher Retirement System of Texas now owns 18,804 shares of the company’s stock worth $168,000 after purchasing an additional 1,641 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Travere Therapeutics by 9.7% during the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock worth $189,000 after purchasing an additional 1,851 shares in the last quarter. Signaturefd LLC boosted its position in shares of Travere Therapeutics by 1,656.4% during the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock worth $27,000 after purchasing an additional 2,849 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Travere Therapeutics by 7.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock worth $417,000 after purchasing an additional 3,083 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of Travere Therapeutics by 4.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 73,400 shares of the company’s stock worth $566,000 after purchasing an additional 3,140 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.